N-tert-Butyl-N'-isopropyl-N,N'-dimethyl-ethane-1,2-diamine | 91964-99-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-tert-Butyl-N'-isopropyl-N,N'-dimethyl-ethane-1,2-diamine
• 英文别名: N'-tert-butyl-N,N'-dimethyl-N-propan-2-ylethane-1,2-diamine
• CAS: 91964-99-7
• 化学式: C₁₁H₂₆N₂
• 分子量: 186.341
• InChiKey: KPHDZANVGQLTDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD.

  公开号：US20170008889A1

  公开（公告）日：2017-01-12

  The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.

  本发明提供了一类2,4-取代苯基-1,5-二胺衍生物，对EGFR酪氨酸激酶具有抑制作用，并提供了该衍生物的药用可接受盐、立体异构体、溶剂合物或前药。有关每个组在公式中的定义，请参阅说明。此外，本发明还揭示了药物组合物、药用可接受组合物及其应用。
• C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE
  申请人：Sugimoto Tomohiro

  公开号：US20140046043A1

  公开（公告）日：2014-02-13

  A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).

  一种大环内酯化合物，化学式为（I），对红霉素耐药的细菌有效（例如，耐药的肺炎球菌，链球菌和支原体）。
• 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US10435400B2

  公开（公告）日：2019-10-08

  The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.

  本发明提供了一类对表皮生长因子受体酪氨酸激酶具有抑制作用的2,4-取代亚苯基-1,5-二胺衍生物，以及上述衍生物的药学上可接受的盐、立体异构体、溶液或原药。式中各基团的定义见说明。此外，本发明还公开了药物组合物、药学上可接受的组合物及其应用。
• 2,4-DISUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND MEDICINAL USE THEREOF
  申请人：Shanghai Haiyan Pharmaceutical Technology Co., Ltd

  公开号：US20170233395A1

  公开（公告）日：2017-08-17

  The present invention relates to a 2,4-disubstituted 7H-pyrrolo[4,3-d]pyrimidin derivative, a preparation method and a medicinal use thereof. In particular, the present invention discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. For the definition of each group in formula (I), see the description tbr details.
• Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：US20180072704A1

  公开（公告）日：2018-03-15

  Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.